We found that elevated levels of Th1 cytokines such as IFN-γ and TNF-α, as well as Th2 cytokines such as IL-5, IL-4, and IL-10, already existing in patients with NSCLC, could reliably predict clinical responses to PD-1 blockade therapies. The gene discussed is IL4; the disease is non-small cell lung carcinoma.